(Q33325625)

25 July 2017

title

Thymostimulin in advanced hepatocellular carcinoma: a phase II trial (English)

1 reference

25 July 2017

main subject

phase II clinical trial

0 references

hepatocellular carcinoma

0 references

author name string

Matthias M Dollinger

1

1 reference

25 July 2017

Christa M Behrens

2

1 reference

25 July 2017

Joachim Lesske

3

1 reference

25 July 2017

Susanne Behl

4

1 reference

25 July 2017

Curd Behrmann

5

1 reference

25 July 2017

Wolfgang E Fleig

6

1 reference

25 July 2017

language of work or name

English

0 references

publication date

13 March 2008

1 reference

25 July 2017

1 reference

25 July 2017

volume

8

1 reference

25 July 2017

page(s)

72

1 reference

Creative Commons Attribution 2.0 Generic

25 July 2017

copyright license

start time

13 March 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2407-8-72

0 references

cites work

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Local/regional and systemic treatments of hepatocellular carcinoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Roles of thymosins in cancers and other organ systems

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Primary liver cancer: worldwide incidence and trends

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Immunobiology and gene-based immunotherapy of hepatocellular carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Thymic hormones in cancer diagnostics and treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma. A report from the Italian Lymphoma Study Group (GISL).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Depressed immune function in patients with cirrhosis before emergence of hepatocellular carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Reporting results of cancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-8-72

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-8-72

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2323008

Activation of human Kupffer cells by thymostimulin (TP-1) to produce cytotoxicity against human hepatocellular cancer

31 October 2018

1 reference

12 December 2020

T and B cell function in alcoholic liver disease

1 reference

12 December 2020

Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder

1 reference

12 December 2020

High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: results of a randomized multicenter clinical trial

1 reference

12 December 2020

Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators

1 reference

12 December 2020

Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis

1 reference

12 December 2020

Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-8-72

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference